Home » News » Drug Sponsors » Nycomed and Almirall partner to market COPD drug

Nycomed and Almirall partner to market COPD drug

Thursday, May 5, 2011

Nycomed and Almirall will become marketing partners for the chronic obstructive pulmonary disease (COPD) treatment Daxas. The two firms have entered into a co-branding agreement covering Spain for Daxas (roflumilast), Nycomed’s once-daily COPD tablet, according to Pharma Times.

Under the terms of the agreement, Nycomed will receive an undisclosed upfront fee from Almirall, which will be exclusively promoting a second brand of the phosphodiesterase 4 (PDE4) enzyme inhibitor.

Almirall’s chief operating officer Luciano Conde said the deal “reinforces our portfolio with a first-in-class product and allows us to leverage our respiratory capabilities and expertise.” He added that the product “has a strong strategic fit in our business and is fully complementary with other bronchodilator treatments in COPD such as our R&D product aclidinium bromide which is expected to be filed this year.”

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!